Head-To-Head Review: Praxis Precision Medicines (NASDAQ:PRAX) versus Sycamore Entertainment Group (OTCMKTS:SEGI)

Sycamore Entertainment Group (OTCMKTS:SEGI) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap consumer discretionary companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Risk and Volatility

Sycamore Entertainment Group has a beta of 54.56, suggesting that its stock price is 5,356% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.66, suggesting that its stock price is 166% more volatile than the S&P 500.

Earnings & Valuation

This table compares Sycamore Entertainment Group and Praxis Precision Medicines”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sycamore Entertainment Group	N/A	N/A	N/A	N/A	N/A
Praxis Precision Medicines	$8.55 million	76.97	-$123.28 million	($10.27)	-3.18

Sycamore Entertainment Group has higher earnings, but lower revenue than Praxis Precision Medicines.

Profitability

This table compares Sycamore Entertainment Group and Praxis Precision Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sycamore Entertainment Group	N/A	N/A	N/A
Praxis Precision Medicines	-9,409.22%	-54.86%	-50.52%

Institutional & Insider Ownership

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 75.5% of Sycamore Entertainment Group shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sycamore Entertainment Group and Praxis Precision Medicines, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sycamore Entertainment Group	0	0	0	0	0.00
Praxis Precision Medicines	1	0	8	0	2.78

Praxis Precision Medicines has a consensus target price of $123.33, indicating a potential upside of 277.74%. Given Praxis Precision Medicines’ stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Sycamore Entertainment Group.

About Sycamore Entertainment Group

Sycamore Entertainment Group, Inc., a diversified entertainment company, which specializes in the acquisition, marketing, and worldwide distribution of feature-length motion pictures. The company is based in Seattle, Washington.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.